Seroatlas · Human Serome Atlas

TAAR2

Trace amine-associated receptor 2

Also known as: GPR58, TAAR2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9P1P5
Gene: TAAR2
Ensembl: ENSG00000146378
Chromosome: 6
Canonical length: 351 aa
Protein class: G-protein coupled receptors, Predicted membrane proteins

OverviewNCBI Gene

Predicted to enable trace-amine receptor activity. Predicted to be involved in G protein-coupled receptor signaling pathway. Predicted to be located in membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

351 residues, UniProt reviewed canonical sequence.

>Q9P1P5|TAAR2
     1  MAVSSEQHEL SHFKRTQTKK EKFNCSEYGN RSCPENERSL GVRVAMYSFM AGSIFITIFG
    61  NLAMIISISY FKQLHTPTNF LILSMAITDF LLGFTIMPYS MIRSVENCWY FGLTFCKIYY
   121  SFDLMLSITS IFHLCSVAID RFYAICYPLL YSTKITIPVI KRLLLLCWSV PGAFAFGVVF
   181  SEAYADGIEG YDILVACSSS CPVMFNKLWG TTLFMAGFFT PGSMMVGIYG KIFAVSRKHA
   241  HAINNLRENQ NNQVKKDKKA AKTLGIVIGV FLLCWFPCFF TILLDPFLNF STPVVLFDAL
   301  TWFGYFNSTC NPLIYGFFYP WFRRALKYIL LGKIFSSCFH NTILCMQKES E

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TAAR2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 7
Mean surface accessibility (rSASA): 0.28
Highest tissue expression: 0.2 nTPM

Expression across tissuesHPA

Tissue

testis: 0.2 nTPM
adipose tissue: 0 nTPM
adrenal gland: 0 nTPM
amygdala: 0 nTPM
appendix: 0 nTPM
basal ganglia: 0 nTPM

Single-cell type

early spermatids: 6.4 nCPM
late spermatids: 2.4 nCPM
gastric chief cells: 1.1 nCPM
granulosa cells: 0.8 nCPM
late primary spermatocytes: 0.7 nCPM
adrenal cortex cells: 0.4 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

amygdala: 0 nTPM
basal ganglia: 0 nTPM
cerebellum: 0 nTPM
cerebral cortex: 0 nTPM
choroid plexus: 0 nTPM
hippocampal formation: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.81
gnomAD pLI: 0
gnomAD missense Z: -0.24
DepMap mean gene effect: -0.03
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 1% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

G protein-coupled receptor signaling pathway

Molecular functions

Cellular components

plasma membrane

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TAAR2 as an antibody target. Whether an autoantibody or antibody against TAAR2 could matter depends on whether native TAAR2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TAAR2 is annotated at the cell surface, where native TAAR2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TAAR2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...